Eli Lilly and Company vs Merck & Co., Inc.
In their latest fiscal years, Eli Lilly and Company reported revenue of $65.18B and Merck & Co., Inc. reported $65.01B — LLY was 1.0× larger by revenue. Net income was $20.64B for LLY and $18.25B for MRK.
| Latest fiscal year | LLY · FY ended Dec 2025 | MRK · FY ended Dec 2025 |
|---|---|---|
| Revenue | $65.18B | $65.01B |
| Revenue growth | +44.7% | +1.3% |
| Net income | $20.64B | $18.25B |
| Net margin | 31.7% | 28.1% |
| Diluted EPS | $22.95 | $7.28 |
| Operating cash flow | $16.81B | $16.47B |
| Total assets | $112.48B | $136.87B |
| Shareholders' equity | $26.54B | $52.61B |
| Cash & equivalents | $7.27B | $14.56B |
Revenue over time
Go deeper
Both columns use the same XBRL concepts where possible, but companies may define revenue and other line items differently. Banks, insurers and industrial companies are not directly comparable on margins. Source: SEC EDGAR XBRL company facts. Not investment advice.